Mirum Pharmaceuticals, Inc. MIRM
Institutional shares held
56.1 Million
25.3K
calls
98.9K
puts
Total value of holdings
$4.08B
$1.84M
calls
$7.2M
puts
Market Cap
$2.64B
36,751,700
Shares Out.
Institutional ownership
152.54%
# of Institutions
230
We take great care to ensure that the data presented and summarized in this overview for Mirum Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIRM
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$488 Million18.24% of portfolio
-
Janus Henderson Group PLC London, X05.24MShares$376 Million0.14% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$232 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.76MShares$198 Million5.52% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$189 Million2.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.56MShares$184 Million0.0% of portfolio
-
Novo Holdings Hellerup, G71.5MShares$108 Million6.65% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.42MShares$102 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.41MShares$101 Million0.01% of portfolio
-
State Street Corp Boston, MA1.38MShares$98.7 Million0.0% of portfolio
Latest Institutional Activity in MIRM
Top Purchases
Top Sells
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Insider Transactions at MIRM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,578
-19.34%
|
$727,928
$76.01 P/Share
|
|
Sep 11
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,333
+27.02%
|
-
|
|
Sep 11
2025
|
Laura Brege |
SELL
Open market or private sale
|
Direct |
17,000
-28.05%
|
$1,258,000
$74.7 P/Share
|
|
Sep 11
2025
|
Laura Brege |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+34.2%
|
$255,000
$15.0 P/Share
|
|
Sep 08
2025
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
17,000
-100.0%
|
-
|
|
Sep 08
2025
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+50.0%
|
$391,000
$23.51 P/Share
|
|
Aug 12
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,954
+8.65%
|
$76,804
$26.49 P/Share
|
|
Aug 11
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-22.08%
|
-
|
|
Aug 11
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
40,000
-22.39%
|
$2,480,000
$62.0 P/Share
|
|
Aug 11
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+18.29%
|
$80,000
$2.94 P/Share
|
|
Aug 07
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
10,000
-80.48%
|
$580,000
$58.0 P/Share
|
|
Aug 07
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.59%
|
$60,000
$6.27 P/Share
|
|
Aug 07
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
40,000
-22.39%
|
$2,200,000
$55.25 P/Share
|
|
Aug 07
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+18.29%
|
$80,000
$2.94 P/Share
|
|
Jul 03
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
477
-16.43%
|
$23,373
$49.08 P/Share
|
|
Jul 02
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
564
-16.27%
|
$27,072
$48.25 P/Share
|
|
Jul 01
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,041
+23.09%
|
-
|
|
Jun 11
2025
|
William Fairey |
SELL
Open market or private sale
|
Direct |
3,203
-56.16%
|
$153,744
$48.42 P/Share
|
|
Jun 03
2025
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$112,500
$45.74 P/Share
|
|
Jun 03
2025
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$35,000
$14.12 P/Share
|
Last 12 Months Summary
Buy / Acquisition
393K
Shares
From
15
Insiders
| Exercise of conversion of derivative security | 386K shares |
|---|---|
| Open market or private purchase | 6.48K shares |
| Grant, award, or other acquisition | 658 shares |
Sell / Disposition
450K
Shares
From
9
Insiders
| Bona fide gift | 103K shares |
|---|---|
| Open market or private sale | 347K shares |